Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the safety and efficacy of Allopregnanolone as a
possible treatment for symptoms of Fragile X-associated Tremor/Ataxia Syndrome (FXTAS).
Phase:
Phase 2
Details
Lead Sponsor:
Randi J. Hagerman, MD University of California, Davis